Celldex Therapeutics, Inc.
CLDX · XNASCIK 744218fmd_06QSYRP78VPN2PNK730G9FWRQRManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 13 | 10 | 4 | 7 | 5 | 2 | 7 | 7 | 2 |
| Cost of revenue | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 5 | 12 | 9 | 3 | 7 | 5 | 2 | 7 | 7 | 1 |
| Research and development | 103 | 96 | 66 | 43 | 43 | 53 | 82 | 118 | 164 | 245 |
| Operating income | (133) | (122) | (156) | (55) | (63) | (71) | (115) | (155) | (195) | (287) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | 4 | 4 | 4 | 4 | 2 | 1 | 3 | 13 | 37 | 29 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | – | – | – |
| Income before taxes | (129) | (117) | (152) | (51) | (61) | (71) | (112) | (141) | (158) | (259) |
| Income tax expense | – | (24) | (1) | – | (1) | (0) | – | 0 | 0 | 0 |
| Net income from continuing operations | – | (93) | (151) | – | (60) | (71) | – | (141) | (158) | (259) |
| Net income | – | – | – | – | – | – | – | (141) | (158) | (259) |
| Net income to common shareholders | (129) | (93) | (151) | (51) | (60) | (71) | (112) | (141) | (158) | (259) |